MicroRNAs: Important modulators of oxLDL-mediated signaling in atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 3, 2013, Pages 215-227

  Zhang, Erli ^a   Wu, Yongjian ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Atherosclerosis; MicroRNA; Oxidized low density lipoprotein

Indexed keywords

CASPASE 4; CHLORDANE; ENDOTHELIN 1; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MICRORNA; MICRORNA 155; MICRORNA 29; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN BAX; PROTEIN BCL 2; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; DENDRITIC CELL; DIAGNOSTIC IMAGING; DNA METHYLATION; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; INTRACELLULAR SIGNALING; MACROPHAGE; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ATHEROSCLEROSIS; DENDRITIC CELLS; EPIGENESIS, GENETIC; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 84875407441     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.15180     Document Type: Review

References (61)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 2006; 367: 1747-1757
2. Lusis AJ: Atherosclerosis. Nature, 2000; 407: 233-241
3. Gustafson B: Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb, 2010; 17: 332-341
4. Jialal I, Devaraj S: The role of oxidized low density lipoprotein in atherogenesis. J Nutr, 1996; 126: 1053S-1057S
5. Levitan I, Volkov S, Subbaiah PV: Oxidized LDL: diver sity, patterns of recognition, and pathophysiology. Antioxid Redox Signal, 2010; 13: 39-75
6. Reddy MA, Natarajan R: Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res, 2011; 90: 421-429
7. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation, 2004; 109: III27-32
8. Navarra T, Del Turco S, Berti S, Basta G: The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb, 2010; 17: 317-331
9. Kowala MC: The role of endothelin in the pathogenesis of atherosclerosis. Adv Pharmacol, 1997; 37: 299-318
10. Rubanyi GM, Polokoff MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev, 1994; 46: 325-415
11. Li D, Yang P, Xiong Q, Song X, Yang X, Liu L, Yuan W, Rui YC: MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J Hypertens, 2010; 28: 1646-1654
12. Mitra S, Khaidakov M, Lu J, Ayyadevara S, Szwedo J, Wang XW, Chen C, Khaidakov S, Kasula SR, Stone A, Pogribny I, Mehta JL: Prior exposure to oxidized lowdensity lipoprotein limits apoptosis in subsequent generations of endothelial cells by altering promoter methylation. Am J Physiol Heart Circ Physiol, 2011; 301: H506-513
13. Qin B, Xiao B, Liang D, Xia J, Li Y, Yang H: MicroRNAs expression in ox-LDL treated HUVECs: MiR-365 modulates apoptosis and Bcl-2 expression. Biochem Biophys Res Commun, 2011; 410: 127-133
14. Li D, Yang B, Mehta JL: Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol, 1998; 275: H568-576
15. Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W: Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J, 2000; 14: 1996-2007
16. Moore KJ, Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell, 2011; 145: 341-355
17. Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, Wang C: MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res, 2009; 83: 131-139
18. Olkkonen VM: Oxysterol binding protein and its homologues: new regulatory factors involved in lipid metabolism. Curr Opin Lipidol, 2004; 15: 321-327
19. Perry RJ, Ridgway ND: Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. Mol Biol Cell, 2006; 17: 2604-2616
20. Yang K, He YS, Wang XQ, Lu L, Chen QJ, Liu J, Sun Z, Shen WF: MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett, 2011; 585: 854-860
21. Maa MC, Chang MY, Li J, Li YY, Hsieh MY, Yang CJ, Chen YJ, Li Y, Chen HC, Cheng WE, Hsieh CY, Cheng CW, Leu TH: The iNOS/Src/FAK axis is critical in Toll-like receptor-mediated cell motility in macrophages. Biochim Biophys Acta, 2011; 1813: 136-147
22. Collins RF, Touret N, Kuwata H, Tandon NN, Grinstein S, Trimble WS: Uptake of oxidized low density lipoprotein by CD36 occurs by an actin-dependent pathway distinct from macropinocytosis. J Biol Chem, 2009; 284: 30288-30297
23. Fitzer-Attas CJ, Lowry M, Crowley MT, Finn AJ, Meng F, DeFranco AL, Lowell CA: Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn. J Exp Med, 2000; 191: 669-682
24. Hazeki K, Masuda N, Funami K, Sukenobu N, Matsumoto M, Akira S, Takeda K, Seya T, Hazeki O: Toll-like receptor-mediated tyrosine phosphorylation of paxillin via MyD88-dependent and-independent pathways. Eur J Immunol, 2003; 33: 740-747
25. Lin YC, Huang DY, Chu CL, Lin WW: Anti-inflammatory actions of Syk inhibitors in macrophages involve nonspecific inhibition of toll-like receptors-mediated JNK signaling pathway. Mol Immunol, 2010; 47: 1569-1578
26. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NFkappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A, 2006; 103: 12481-12486
27. Akira S, Takeda K: Toll-like receptor signalling. Nature reviews Immunology, 2004; 4: 499-511
28. de Winther MP, Kanters E, Kraal G, Hofker MH: Nuclear factor kappaB signaling in atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005; 25: 904-914
29. Huang RS, Hu GQ, Lin B, Lin ZY, Sun CC: MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. Journal of investigative medicine: the official publication of the American Federation for Clinical Research, 2010; 58: 961-967
30. Chen T, Yan H, Li Z, Jing T, Zhu W, Ge J, Zheng X, Pan X, Zhu J: MicroRNA-155 regulates lipid uptake, adhesion/ chemokine marker secretion and SCG2 expression in oxLDL-stimulated dendritic cells/macrophages. International Journal of Cardiology, 2011; 147: 446-447
31. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Medicine, 2004; 10: 416-421
32. Tang B, Xiao B, Liu Z, Li N, Zhu ED, Li BS, Xie QH, Zhuang Y, Zou QM, Mao XH: Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Letters, 2010; 584: 1481-1486
33. Leon B, Lopez-Bravo M, Ardavin C: Monocyte-derived dendritic cells. Seminars in Immunology, 2005; 17: 313-318
34. Chen T, Li Z, Jing T, Zhu W, Ge J, Zheng X, Pan X, Yan H, Zhu J: MicroRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells. FEBS Letters, 2011; 585: 567-573
35. Niessner A, Weyand CM: Dendritic cells in atherosclerotic disease. Clin Immunol, 2010; 134: 25-32
36. Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E: CD40/CD40L signaling and its implication in health and disease. Biofactors, 2009; 35: 474-483
37. Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O: MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis and Rheumatism, 2010; 62: 1733-1743
38. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell, 2008; 14: 369-381
39. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2008; 105: 13027-13032
40. Chen T, Li Z, Tu J, Zhu W, Ge J, Zheng X, Yang L, Pan X, Yan H, Zhu J: MicroRNA-29a regulates pro-inflammatory cytokine secretion and scavenger receptor expression by targeting LPL in oxLDL-stimulated dendritic cells. FEBS Letters, 2011; 585: 657-663
41. Qiu G, Ho AC, Yu W, Hill JS: Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinflammatory cytokine secretion. Journal of Lipid Research, 2007; 48: 385-394
42. Rudijanto A: The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta medica Indonesiana, 2007; 39: 86-93
43. Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, Dai CY, Juo SH: OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 2011; 25: 1718-1728
44. Chen KC, Liao YC, Hsieh IC, Wang YS, Hu CY, Juo SH: OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: Novel mechanisms for cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 2011;
45. Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL: Lectinlike oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis. The Biochemical Journal, 2006; 393: 255-265
46. Chen KC, Hsieh IC, Hsi E, Wang YS, Dai CY, Chou WW, Juo SH: Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1. Journal of Cell Science, 2011; 124: 4115-4124
47. Greer EL, Maures TJ, Ucar D, Hauswirth AG, Mancini E, Lim JP, Benayoun BA, Shi Y, Brunet A: Transgenerational epigenetic inheritance of longevity in Caenorhabditis elegans. Nature, 2011; 479: 365-371
48. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R: Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2008; 105: 9047-9052
49. Kang S, Wu Y, Li X: Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis, 2004; 177: 433-442
50. Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L, Natarajan R: Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes, 2010; 59: 2904-2915
51. Tousoulis D: Editorial inflammation in atherosclerosis: current therapeutic approaches. Current Pharmaceutical Design, 2011; 17: 4087-4088
52. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA: the journal of the American Medical Association, 2003; 290: 898-904
53. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004; 364: 937-952
54. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D, Stefanadis C: Vulnerable plaque and inflammation: potential clinical strategies. Current Pharmaceutical Design, 2011; 17: 4190-4209
55. Mause SF, Weber C: Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation Research, 2010; 107: 1047-1057
56. Reid G, Kirschner MB, van Zandwijk N: Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology, 2011; 80: 193-208
57. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biology, 2011; 13: 423-433
58. Heightman TD: Therapeutic prospects for epigenetic modulation. Expert Opinion on Therapeutic Targets, 2011; 15: 729-740
59. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, Park M, Kim M: Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Molecular therapy: the journal of the American Society of Gene Therapy, 2007; 15: 1145-1152
60. Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M, Lyko F: Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Research, 2005; 65: 6305-6311
61. Pogribny IP, Beland FA: DNA hypomethylation in the origin and pathogenesis of human diseases. Cellular and Molecular Life Sciences: CMLS, 2009; 66: 2249-2261